Symbols / CTOR Stock $0.72 -10.01% Citius Oncology, Inc.
CTOR (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.
Ratings
Current target
$0.72
Low
$4.00
High
$4.00
Mean
$4.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-23 | up | Maxim Group | Hold → Buy | $6 |
| 2025-05-23 | down | Maxim Group | Buy → Hold | — |
| 2024-11-27 | init | Maxim Group | — → Buy | $3 |
| 2024-08-13 | main | EF Hutton | Buy → Buy | $6 |
- Citius Oncology (CTOR) stake updated by majority holder Citius Pharma - Stock Titan hu, 04 Jun 2026 20
- CITIUS ONCOLOGY INC (CTOR) Stock Chart - ChartMill Fri, 05 Jun 2026 07
- Citius Oncology, Inc. Financial Disclosures & SEC Filings - TradingView hu, 04 Jun 2026 11
- Citius Oncology, Inc.'s (NASDAQ:CTOR) Path To Profitability - simplywall.st hu, 30 Apr 2026 07
- Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization - PR Newswire ue, 05 May 2026 07
- Citius Oncology (CTOR) registers 6.8M warrant shares; highlights Phase 1 LYMPHIR data - Stock Titan Mon, 01 Jun 2026 20
- CITIUS ONCOLOGY Q1 2026 Earnings Preview: Recent $CTOR Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative Wed, 11 Feb 2026 08
- Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV) and Citius Oncology (CTOR) - The Globe and Mail hu, 21 May 2026 07
- CTOR Stock Price and Chart — NASDAQ:CTOR - TradingView Mon, 16 Mar 2026 07
- Citius Oncology Ships First International Order of LYMPHIR™ to Europe - PR Newswire Wed, 29 Apr 2026 07
- LYMPHIR combo study finds 24% response, disease control up to 35 months - Stock Titan Mon, 01 Jun 2026 11
- Number of shareholders of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView ue, 26 May 2026 17
- Citius Oncology (Nasdaq: CTOR) registers 32.9M shares tied to warrants and loan conversion - Stock Titan Fri, 29 May 2026 20
- Citius Oncology (CTOR) registers 6.82M warrant shares; May 2026 financing steps - Stock Titan Fri, 22 May 2026 07
- Citius Oncology (NASDAQ: CTOR) majority approves warrant and conversion issuances - Stock Titan ue, 19 May 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
23.52
+14.34%
|
20.57
+69.72%
|
12.12
+149.58%
|
4.86
|
| Research And Development |
|
6.42
+30.32%
|
4.93
+16.14%
|
4.24
+23.71%
|
3.43
|
| Selling General And Administration |
|
17.10
+9.31%
|
15.65
+98.56%
|
7.88
+451.59%
|
1.43
|
| General And Administrative Expense |
|
17.10
+9.31%
|
15.65
+98.56%
|
7.88
+451.59%
|
1.43
|
| Salaries And Wages |
|
8.32
+10.96%
|
7.50
+281.52%
|
1.97
|
0.00
|
| Other Gand A |
|
8.78
+7.79%
|
8.15
+37.76%
|
5.92
+314.02%
|
1.43
|
| Total Expenses |
|
23.52
+14.34%
|
20.57
+69.72%
|
12.12
+149.58%
|
4.86
|
| Operating Income |
|
-23.52
-14.34%
|
-20.57
-69.72%
|
-12.12
-149.58%
|
-4.86
|
| Total Operating Income As Reported |
|
-23.52
-14.34%
|
-20.57
|
—
|
—
|
| EBITDA |
|
-23.49
-14.16%
|
-20.57
-69.72%
|
-12.12
-149.58%
|
-4.86
|
| Normalized EBITDA |
|
-23.49
-14.16%
|
-20.57
-69.72%
|
-12.12
-149.58%
|
-4.86
|
| EBIT |
|
-23.49
-14.16%
|
-20.57
-69.72%
|
-12.12
-149.58%
|
-4.86
|
| Net Income |
|
-24.76
-17.08%
|
-21.15
-66.56%
|
-12.70
-133.72%
|
-5.43
|
| Pretax Income |
|
-23.70
-15.22%
|
-20.57
-69.72%
|
-12.12
-149.58%
|
-4.86
|
| Net Non Operating Interest Income Expense |
|
-0.18
|
0.00
|
—
|
—
|
| Interest Expense Non Operating |
|
0.22
|
0.00
|
—
|
—
|
| Net Interest Income |
|
-0.18
|
0.00
|
—
|
—
|
| Interest Expense |
|
0.22
|
0.00
|
—
|
—
|
| Interest Income Non Operating |
|
0.04
|
0.00
|
—
|
—
|
| Interest Income |
|
0.04
|
0.00
|
—
|
—
|
| Tax Provision |
|
1.06
+83.50%
|
0.58
+0.00%
|
0.58
+0.00%
|
0.58
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-24.76
-17.08%
|
-21.15
-66.56%
|
-12.70
-133.72%
|
-5.43
|
| Net Income From Continuing Operation Net Minority Interest |
|
-24.76
-17.08%
|
-21.15
-66.56%
|
-12.70
-133.72%
|
-5.43
|
| Net Income From Continuing And Discontinued Operation |
|
-24.76
-17.08%
|
-21.15
-66.56%
|
-12.70
-133.72%
|
-5.43
|
| Net Income Continuous Operations |
|
-24.76
-17.08%
|
-21.15
-66.56%
|
-12.70
-133.72%
|
-5.43
|
| Normalized Income |
|
-24.76
-17.08%
|
-21.15
-66.56%
|
-12.70
-133.72%
|
-5.43
|
| Net Income Common Stockholders |
|
-24.76
-17.08%
|
-21.15
-66.56%
|
-12.70
-133.72%
|
-5.43
|
| Diluted EPS |
|
-0.34
-9.68%
|
-0.31
-73.93%
|
-0.18
-133.72%
|
-0.08
|
| Basic EPS |
|
-0.34
-9.68%
|
-0.31
-73.93%
|
-0.18
-133.72%
|
-0.08
|
| Basic Average Shares |
|
73.27
+7.66%
|
68.05
-4.47%
|
71.24
+0.00%
|
71.24
|
| Diluted Average Shares |
|
73.27
+7.66%
|
68.05
-4.47%
|
71.24
+0.00%
|
71.24
|
| Diluted NI Availto Com Stockholders |
|
-24.76
-17.08%
|
-21.15
-66.56%
|
-12.70
-133.72%
|
-5.43
|
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Total Assets |
|
100.94
+19.64%
|
84.37
+76.74%
|
47.73
+11.82%
|
42.69
|
| Current Assets |
|
27.54
+151.10%
|
10.97
+41.81%
|
7.73
+187.52%
|
2.69
|
| Cash Cash Equivalents And Short Term Investments |
|
3.92
+3504282.14%
|
0.00
|
0.00
|
0.00
|
| Cash And Cash Equivalents |
|
3.92
+3504282.14%
|
0.00
|
0.00
|
0.00
|
| Inventory |
|
22.29
+169.53%
|
8.27
|
0.00
|
—
|
| Work In Process |
|
11.71
+448.71%
|
2.13
|
—
|
—
|
| Finished Goods |
|
10.58
+72.42%
|
6.13
|
—
|
—
|
| Prepaid Assets |
|
1.33
-50.69%
|
2.70
-65.09%
|
7.73
+187.52%
|
2.69
|
| Total Non Current Assets |
|
73.40
+0.00%
|
73.40
+83.50%
|
40.00
+0.00%
|
40.00
|
| Goodwill And Other Intangible Assets |
|
73.40
+0.00%
|
73.40
+83.50%
|
40.00
+0.00%
|
40.00
|
| Other Intangible Assets |
|
73.40
+0.00%
|
73.40
+83.50%
|
40.00
+0.00%
|
40.00
|
| Total Liabilities Net Minority Interest |
|
56.08
+46.69%
|
38.23
+72.21%
|
22.20
+245.63%
|
6.42
|
| Current Liabilities |
|
49.49
+51.35%
|
32.70
+55.37%
|
21.05
+259.98%
|
5.85
|
| Payables And Accrued Expenses |
|
49.49
+51.35%
|
32.70
+55.37%
|
21.05
+259.98%
|
5.85
|
| Payables |
|
45.40
+38.83%
|
32.70
+57.30%
|
20.79
+334.36%
|
4.79
|
| Accounts Payable |
|
13.23
+256.57%
|
3.71
+187.94%
|
1.29
+1296.42%
|
0.09
|
| Other Payable |
|
22.65
-20.25%
|
28.40
|
—
|
—
|
| Current Accrued Expenses |
|
4.09
|
0.00
-100.00%
|
0.26
-75.58%
|
1.06
|
| Other Current Liabilities |
|
—
|
0.00
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
6.59
+19.12%
|
5.53
+379.87%
|
1.15
+100.00%
|
0.58
|
| Long Term Debt And Capital Lease Obligation |
|
3.80
+0.00%
|
3.80
|
—
|
—
|
| Long Term Debt |
|
3.80
+0.00%
|
3.80
|
—
|
—
|
| Non Current Deferred Liabilities |
|
2.78
+61.17%
|
1.73
+50.00%
|
1.15
+100.00%
|
0.58
|
| Non Current Deferred Taxes Liabilities |
|
2.78
+61.17%
|
1.73
+50.00%
|
1.15
+100.00%
|
0.58
|
| Other Non Current Liabilities |
|
—
|
-0.00
|
—
|
—
|
| Stockholders Equity |
|
44.87
-2.76%
|
46.14
+80.69%
|
25.54
-29.59%
|
36.27
|
| Common Stock Equity |
|
44.87
-2.76%
|
46.14
+80.69%
|
25.54
-29.59%
|
36.27
|
| Capital Stock |
|
0.01
+16.72%
|
0.01
+6.00%
|
0.01
+0.00%
|
0.01
|
| Common Stock |
|
0.01
+16.72%
|
0.01
+6.00%
|
0.01
+0.00%
|
0.01
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
83.51
+16.72%
|
71.55
+0.44%
|
71.24
+0.00%
|
71.24
|
| Ordinary Shares Number |
|
83.51
+16.72%
|
71.55
+0.44%
|
71.24
+0.00%
|
71.24
|
| Additional Paid In Capital |
|
108.90
+27.50%
|
85.41
+95.63%
|
43.66
+4.71%
|
41.69
|
| Retained Earnings |
|
-64.04
-63.04%
|
-39.28
-116.65%
|
-18.13
-233.72%
|
-5.43
|
| Total Equity Gross Minority Interest |
|
44.87
-2.76%
|
46.14
+80.69%
|
25.54
-29.59%
|
36.27
|
| Total Capitalization |
|
48.67
-2.55%
|
49.94
+95.57%
|
25.54
-29.59%
|
36.27
|
| Working Capital |
|
-21.95
-1.00%
|
-21.73
-63.24%
|
-13.31
-321.73%
|
-3.16
|
| Invested Capital |
|
48.67
-2.55%
|
49.94
+95.57%
|
25.54
-29.59%
|
36.27
|
| Total Debt |
|
3.80
+0.00%
|
3.80
|
—
|
—
|
| Net Debt |
|
—
|
3.80
|
—
|
—
|
| Net Tangible Assets |
|
-28.53
-4.67%
|
-27.26
-88.46%
|
-14.46
-287.51%
|
-3.73
|
| Tangible Book Value |
|
-28.53
-4.67%
|
-27.26
-88.46%
|
-14.46
-287.51%
|
-3.73
|
| Dueto Related Parties Current |
|
9.51
+1515.77%
|
0.59
-96.98%
|
19.50
+315.44%
|
4.69
|
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-5.49
-4446.59%
|
0.13
|
0.00
|
0.00
|
| Cash Flow From Continuing Operating Activities |
|
-5.49
-4446.59%
|
0.13
|
0.00
|
0.00
|
| Net Income From Continuing Operations |
|
-24.76
-17.08%
|
-21.15
-66.56%
|
-12.70
-133.72%
|
-5.43
|
| Stock Based Compensation |
|
8.32
+10.96%
|
7.50
+281.52%
|
1.97
|
0.00
|
| Deferred Tax |
|
1.06
+83.50%
|
0.58
+0.00%
|
0.58
+0.00%
|
0.58
|
| Deferred Income Tax |
|
1.06
+83.50%
|
0.58
+0.00%
|
0.58
+0.00%
|
0.58
|
| Change In Working Capital |
|
9.89
-25.06%
|
13.20
+29.98%
|
10.16
+109.11%
|
4.86
|
| Change In Inventory |
|
-12.65
-492.78%
|
-2.13
|
0.00
|
—
|
| Change In Prepaid Assets |
|
0.00
+100.00%
|
-1.10
+78.19%
|
-5.04
-409.47%
|
-0.99
|
| Change In Payables And Accrued Expense |
|
22.54
+37.16%
|
16.43
+8.12%
|
15.20
+159.98%
|
5.85
|
| Change In Accrued Expense |
|
4.09
+1679.92%
|
-0.26
+67.69%
|
-0.80
-175.58%
|
1.06
|
| Change In Payable |
|
18.45
+10.51%
|
16.69
+4.32%
|
16.00
+234.36%
|
4.79
|
| Change In Account Payable |
|
9.52
+293.10%
|
2.42
+102.43%
|
1.20
+1196.42%
|
0.09
|
| Investing Cash Flow |
|
-5.75
-15.00%
|
-5.00
|
0.00
|
—
|
| Cash Flow From Continuing Investing Activities |
|
-5.75
-15.00%
|
-5.00
|
0.00
|
—
|
| Capital Expenditure |
|
-5.75
-15.00%
|
-5.00
|
—
|
—
|
| Net Intangibles Purchase And Sale |
|
-5.75
-15.00%
|
-5.00
|
0.00
|
—
|
| Purchase Of Intangibles |
|
-5.75
-15.00%
|
-5.00
|
0.00
|
—
|
| Financing Cash Flow |
|
15.17
+211.19%
|
4.87
|
0.00
|
—
|
| Cash Flow From Continuing Financing Activities |
|
15.17
+211.19%
|
4.87
|
0.00
|
—
|
| Net Issuance Payments Of Debt |
|
0.00
-100.00%
|
3.80
|
0.00
|
—
|
| Issuance Of Debt |
|
0.00
-100.00%
|
3.80
|
0.00
|
—
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
3.80
|
0.00
|
—
|
| Net Long Term Debt Issuance |
|
0.00
-100.00%
|
3.80
|
0.00
|
—
|
| Net Common Stock Issuance |
|
15.17
|
0.00
|
—
|
—
|
| Net Other Financing Charges |
|
—
|
1.07
|
—
|
—
|
| Changes In Cash |
|
3.92
+3504182.14%
|
0.00
|
—
|
—
|
| Beginning Cash Position |
|
0.00
|
0.00
|
0.00
|
0.00
|
| End Cash Position |
|
3.92
+3504282.14%
|
0.00
|
0.00
|
0.00
|
| Free Cash Flow |
|
-11.24
-130.67%
|
-4.87
|
0.00
|
0.00
|
| Common Stock Issuance |
|
15.17
|
0.00
|
—
|
—
|
| Issuance Of Capital Stock |
|
15.17
|
0.00
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-06-01 View
- 8-K2026-05-15 View
- 10-Q2026-05-15 View
- 8-K2026-05-06 View
- 8-K2026-04-29 View
- 8-K2026-04-28 View
- 8-K2026-03-31 View
- 8-K2026-03-10 View
- 8-K2026-03-04 View
- 8-K2026-02-13 View
- 10-Q2026-02-13 View
- 8-K2025-12-23 View
- 10-K2025-12-23 View
- 8-K2025-12-10 View
- 8-K2025-12-01 View
- 8-K2025-10-27 View
- 8-K2025-10-23 View
- 42025-09-23 View
- 42025-09-23 View
- 42025-09-23 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|